| Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG … JAMA Oncology, 2018 | 160 | 2018 |
| Histone deacetylase inhibitors: emerging mechanisms of resistance RW Robey, AR Chakraborty, A Basseville, V Luchenko, J Bahr, Z Zhan, ... Molecular pharmaceutics 8 (6), 2021-2031, 2011 | 142 | 2011 |
| SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer AC Erica Hlavin Bell1,*, Arup R Chakraborty1, Xiaokui Mo2, Ziyan Liu1 ... Clinical Cancer Research, 2015 | 127* | 2015 |
| MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor AR Chakraborty, RW Robey, VL Luchenko, Z Zhan, RL Piekarz, JP Gillet, ... Blood, The Journal of the American Society of Hematology 121 (20), 4115-4125, 2013 | 90 | 2013 |
| Circulating microRNAs in cancer: Hope or hype? CA Singh R1, Ramasubramanian B1, Kanji S1, Chakraborty AR1, Haque SJ1 Cancer Letters, 2016 | 81 | 2016 |
| Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin VL Luchenko, T Litman, AR Chakraborty, A Heffner, C Devor, J Wilkerson, ... Molecular oncology 8 (8), 1379-1392, 2014 | 48 | 2014 |
| Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors C Ieranò, A Chakraborty, A Nicolae, J Bahr, Z Zhan, S Pittaluga, S Bates, ... Cell Cycle 12 (17), 2829-2838, 2013 | 37 | 2013 |
| Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen JF Deeken, RW Robey, S Shukla, K Steadman, AR Chakraborty, ... Molecular pharmacology 76 (5), 946-956, 2009 | 36 | 2009 |
| Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. BSE Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H ... Oncotarget, 2016 | 17 | 2016 |
| R-loop–mediated ssDNA breaks accumulate following short-term exposure to the HDAC inhibitor romidepsin M Safari, T Litman, RW Robey, A Aguilera, AR Chakraborty, WC Reinhold, ... Molecular Cancer Research 19 (8), 1361-1374, 2021 | 14 | 2021 |
| PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19 J Logue, AR Chakraborty, R Johnson, G Goyal, M Rodas, LJ Taylor, ... Communications Biology 5 (1), 808, 2022 | 11 | 2022 |
| Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors AR Chakraborty, A Vassilev, SK Jaiswal, CE O'Connell, JF Ahrens, ... Stem Cell Reports 17 (2), 397-412, 2022 | 6 | 2022 |
| PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells A Roy, AR Chakraborty, T Nomanbhoy, ML DePamphilis Autophagy 19 (9), 2464-2484, 2023 | 5 | 2023 |
| Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT+ PCV in high-risk low-grade gliomas (LGGs). EH Bell, JP McElroy, J Fleming, CD Timmers, AR Chakraborty, ... Journal of Clinical Oncology 34 (15_suppl), 2017-2017, 2016 | 3 | 2016 |
| Novel putative diagnostic methylation biomarkers for prostate cancer identified by whole genome DNA methylation profiling AR Chakraborty, E Hlavin Bell, S Kriste, V Drendel, J McElRoy, M Werner, ... Cancer Research 76 (14_Supplement), 2781-2781, 2016 | 1 | 2016 |
| PIKFYVE inhibitors trigger interleukin‐24‐dependent cell death of autophagy‐dependent melanoma A Roy, AR Chakraborty, ML DePamphilis Molecular Oncology, 2024 | | 2024 |
| Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT plus TMZ vs RT plus nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma … EH Bell, JP McElroy, J Fleming, CD Timmers, AR Chakraborty, ... JOURNAL OF CLINICAL ONCOLOGY 34 (15), 2016 | | 2016 |
| Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT+ TMZ vs RT+ nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma … EH Bell, JP McElroy, J Fleming, CD Timmers, AR Chakraborty, ... Journal of Clinical Oncology 34 (15_suppl), 2016-2016, 2016 | | 2016 |
